© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
Irritable Bowel Syndrome: Helping Patients Access Appropriate Treatment in an Era of Investigation and Discovery
This Continuing Education activity is supported by an independent educational grant from Allergan Inc. and Prometheus Laboratories, Inc.
This activity is supported by an independent educational grant from Allergan Inc. and Prometheus Laboratories, Inc.
Faculty
Mary Barna Bridgeman, PharmD, BCPS,
CGP
Clinical Associate Professor
Department of Pharmacy Practice and Administration
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, New Jersey
Marc G. Sturgill, PharmD
Associate Professor and Chairman
Department of Pharmacy Practice and Administration
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, New Jersey
Educational Objectives
After completing this continuing education program, the participant will be able to:
- Differentiate the clinical signs and symptoms of irritable bowel syndrome (IBS), including indicators of type and severity, and other conditions to rule out in a differential diagnosis.
- Demonstrate knowledge of the appropriate indications, mechanisms of action, dosing, possible drug interactions, and major adverse effects of available and emerging IBS treatments.
- Examine patients’ symptoms, medical status, disease severity, and possible contraindications to OTC treatment in patients with IBS.
Target audience: Pharmacists
Type of activity: Application
Release date: November 7, 2015
Expiration date: November 7, 2016
Estimated time to complete activity: 2.0 hours
Fee: Free
Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-15-142-H01-P. The activity is available for CE credit through November 7, 2016.